Skip to search boxSkip to navigationSkip to main content

Prior Antithrombotic Use is Associated with Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke

  • Phyo K. Myint(corresponding author)
    ,
  • Anne S. Hellkamp
    ,
  • Gregg C. Fonarow
    ,
  • Matthew J. Reeves
    ,
  • Lee H. Schwamm
    ,
  • Phillip J. Schulte
*Corresponding author for this work
  • University of Aberdeen
    ,
  • Duke University
    ,
  • University of California at Los Angeles
    ,
  • Michigan State University
    ,
  • Harvard University
    ,
  • Mayo Clinic Rochester, MN
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Background and Purpose - Antithrombotics are the mainstay of treatment in primary and secondary prevention of stroke, and their use before an acute event may be associated with better outcomes. Methods - Using data from Get With The Guidelines-Stroke with over half a million acute ischemic strokes recorded between October 2011 and March 2014 (n=540 993) from 1661 hospitals across the United States, we examined the unadjusted and adjusted associations between previous antithrombotic use and clinical outcomes. Results - There were 250 104 (46%) stroke patients not receiving any antithrombotic before stroke; of whom approximately one third had a documented previous vascular indication. After controlling for clinical and hospital factors, patients who were receiving antithrombotics before stroke had better outcomes than those who did not, regardless of whether a previous vascular indication was present or not: adjusted odds ratio (95% confidence intervals) were 0.82 (0.80-0.84) for in-hospital mortality, 1.18 (1.16-1.19) for home as the discharge destination, 1.15 (1.13-1.16) for independent ambulatory status at discharge, and 1.15 (1.12-1.17) for discharge modified Rankin Scale score of 0 or 1. Conclusions - Previous antithrombotic therapy was independently associated with improved clinical outcomes after acute ischemic stroke. Ensuring the use of antithrombotics in appropriate patient populations may be associated with benefits beyond stroke prevention.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 2066-2074 (9 pages)

Journal (Volume, Issue Number)

Stroke (Volume 47, Issue 8)

Publication milestones

  • Published - 08/01/2016

Publication status

Published - 08/01/2016

ISSN

0039-2499

Publication IDs

  • Scopus: 84979055361
  • PubMed: 27435402

Publication metrics

Metrics

Scopus
citations
SciVal
FWCI
0.85
SciVal
Author count
12
SciVal
citations
8
SciVal
Paper percentile
67
Fractional count
1
Fractional count
0.08
Fractional count
11
Fractional count
0.92
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
14
Captures
41
Mentions
1

Funding Details

Sources of Funding The Get With The Guidelines (GWTG)-Stroke program is currently supported, in part, by a charitable contribution from Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership and the American Heart Association Pharmaceutical Roundtable. GWTG-Stroke has been funded in the past through support from Boehringer-Ingelheim and Merck. These funding agencies did not participate in design or analysis, article preparation, or approval of this study.
FundersFunding numbers
American Heart Association Pharmaceutical Roundtable
-
Sanofi Pharmaceutical Partnership
-
BI
-
Merck
-